US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (NQ:CYCCP)

5.050 UNCHANGED
Last Price Updated: 3:01 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

< Previous 1 2 3 Next >
News headline image
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Reverse Stock Split
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
From Cyclacel
Via GlobeNewswire
< Previous 1 2 3 Next >